| Drug Name: | Methysergide (361-37-5) |
|---|---|
| PubChem ID: | 9681 |
| SMILES: | CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C |
| InchiKey: | KPJZHOPZRAFDTN-ZRGWGRIASA-N |
| Therapeutic Category: | Cardiovascular Agents, Neurotransmitter Agents, Serotonin Agents, Serotonin Antagonists, Vasoconstrictor Agents |
| Molecular Weight (dalton) | : | 353.466 |
| LogP | : | 1.9351 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 57.5 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Ergotamine (113-15-5) | Ischaemia | Synergistic | Cluster headaches are associated with abnormal dilatation of the carotid arteries, which can be constricted by ergot derivatives. In the cases cited it would seem that combined vasoconstrictor effects caused arterial spasm elsewhere in the body | Arterial complications of migraine treatment with methysergide and parenteral ergotamine |
| Delavirdine (136817-59-9) | Ergotism | Synergistic | The ergot alkaloids are mainly metabolised by the cytochrome P450 isoenzyme CYP3A4.Delavirdine is CYP3A4 inhibitor | Catalytic inhibition of human DNA topoisomerase II? by hypericin, a naphthodianthrone from St John’s wort (Hypericum perforatum) |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category